SAN DIEGO, Dec. 5, 2016 /PRNewswire-USNewswire/ -- Renova Therapeutics, a biotechnology company developing gene therapy treatments for congestive heart failure and other chronic diseases, announced that Catherine Bovenizer, CPA, is joining the company as Chief Financial Officer (CFO), effective today.
Ms. Bovenizer joins Renova Therapeutics with 20 years of experience in financial management for a variety of public and closely held biotech and software companies. Most recently, Ms. Bovenizer was the Vice President of Finance and Chief Accounting Officer at Apricus Biosciences. In this role, she oversaw the team responsible for full-cycle accounting, audit management, accounting policy and procedure implementation, SEC reporting, human resources and IT/facilities, along with supporting investor relations.
As CFO of Renova Therapeutics, Ms. Bovenizer will be responsible for overseeing and directing the company’s financial goals and objectives, reporting to Roy Cosan, President of Renova Therapeutics. She will meet quarterly with the Renova Therapeutics Board of Directors and other company executives to set and implement the organization’s budgets. Her primary responsibilities include all aspects of accounting, cash flow management, employee benefits, and the facilitation of external company valuation efforts, along with managing grants from the National Institutes of Health. Ms. Bovenizer will also take on human resources and IT management responsibilities. Communications including investor relations and public relations will report to her.
“As a development-stage biotech that continues to grow, we know it’s critical to continue to manage our finances with extreme diligence and with focus on value creation,” says Mr. Cosan. “That’s why the addition of Cath as CFO was of utmost importance to us. Her experience in financial management within both private and public biotechnology companies is vital to our success.”
Ms. Bovenizer graduated magna cum laude from Claremont McKenna College in Claremont, Calif., with a B.A. in Economics, Accounting and Literature. Prior to her most recent role at Apricus, she held roles of increasing responsibility at Ambit Biosciences, Senomyx, Ligand Pharmaceuticals and GeneFormatics. Ms. Bovenizer began her career at Coopers & Lybrand.
“I’m thrilled to join an organization that’s poised to be a game-changer in how we look at and treat chronic diseases,” says Ms. Bovenizer. “I look forward to seeing what we accomplish as a team.”
About Renova Therapeutics
Renova Therapeutics is developing definitive, one-time gene therapies and peptide infusion treatments to restore the health of people suffering from chronic diseases. The first indications the company is pursuing are gene therapy treatments for congestive heart failure (CHF) and type 2 diabetes, two of the most common and devastating chronic diseases in the world. The company’s lead product, RT-100, is a treatment that delivers a therapeutic gene directly to the heart during a routine outpatient procedure and has the potential to increase heart function in millions of patients with CHF. The company’s product pipeline also includes a groundbreaking gene therapy in preclinical stage for sufferers of type 2 diabetes, as well as a peptide infusion therapy for the treatment of acute decompensated heart failure. Renova Therapeutics was founded in 2009 and is led by an experienced management team in biopharmaceuticals and gene therapy. For additional information about the company, please visit www.renovatherapeutics.com.
Photo - http://photos.prnewswire.com/prnh/20161202/445113
Logo - http://photos.prnewswire.com/prnh/20151231/318660LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biotech-finance-expert-joins-renova-therapeutics-as-cfo-300372276.html
SOURCE Renova Therapeutics
